MA34670B1 - Inhibiteurs de l'apoptose et leurs utilisations - Google Patents

Inhibiteurs de l'apoptose et leurs utilisations

Info

Publication number
MA34670B1
MA34670B1 MA35909A MA35909A MA34670B1 MA 34670 B1 MA34670 B1 MA 34670B1 MA 35909 A MA35909 A MA 35909A MA 35909 A MA35909 A MA 35909A MA 34670 B1 MA34670 B1 MA 34670B1
Authority
MA
Morocco
Prior art keywords
fragments
apoptosis
conjugates
derivatives
pharmaceutical compositions
Prior art date
Application number
MA35909A
Other languages
English (en)
Inventor
Stephanie Barrere
Joel Nargeot
Bernard Lebleu
Prisca Boisguerin
Christophe Piot
Original Assignee
Centre Nat Rech Scient
Univ Montpellier Ii
Univ Montpellier 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43880951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34670(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre Nat Rech Scient, Univ Montpellier Ii, Univ Montpellier 1 filed Critical Centre Nat Rech Scient
Publication of MA34670B1 publication Critical patent/MA34670B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des fragments des protéines DAXX et FADD qui inhibent l'apoptose cellulaire, en particulier l'apoptose cellulaire à médiation par le récepteur Fas. L'invention concerne également des dérivés desdits fragments anti-apoptotiques, des conjugués comprenant lesdits fragments, des compositions pharmaceutiques comprenant lesdits fragments et les applications médicales desdits fragments, dérivés, conjugués, et compositions pharmaceutiques de ceux-ci dans le traitement ou la prévention de maladies et d'états pathologiques associés à l'apoptose.
MA35909A 2010-11-18 2013-05-15 Inhibiteurs de l'apoptose et leurs utilisations MA34670B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2010/003158 WO2012066376A1 (fr) 2010-11-18 2010-11-18 Inhibiteurs de l'apoptose et leurs utilisations
PCT/EP2011/070404 WO2012066103A2 (fr) 2010-11-18 2011-11-17 Inhibiteurs de l'apoptose et leurs utilisations

Publications (1)

Publication Number Publication Date
MA34670B1 true MA34670B1 (fr) 2013-11-02

Family

ID=43880951

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35909A MA34670B1 (fr) 2010-11-18 2013-05-15 Inhibiteurs de l'apoptose et leurs utilisations

Country Status (36)

Country Link
US (1) US9814758B2 (fr)
EP (2) EP2640739B1 (fr)
JP (1) JP6204828B2 (fr)
KR (2) KR101913285B1 (fr)
CN (2) CN106188271B (fr)
AU (1) AU2011331103B2 (fr)
BR (1) BR112013012362A2 (fr)
CA (2) CA3078178C (fr)
CL (1) CL2013001411A1 (fr)
CO (1) CO6700879A2 (fr)
CR (1) CR20130190A (fr)
CY (1) CY1118022T1 (fr)
DK (1) DK2640739T3 (fr)
EA (1) EA027336B1 (fr)
ES (2) ES2653734T3 (fr)
GE (1) GEP201606514B (fr)
GT (1) GT201300117A (fr)
HK (1) HK1184791A1 (fr)
HR (1) HRP20151165T1 (fr)
HU (1) HUE026150T2 (fr)
IL (2) IL226005B (fr)
MA (1) MA34670B1 (fr)
ME (1) ME02291B (fr)
MX (1) MX345594B (fr)
MY (1) MY170604A (fr)
NI (1) NI201300045A (fr)
NZ (1) NZ610620A (fr)
PL (1) PL2640739T3 (fr)
PT (1) PT2640739E (fr)
RS (1) RS54422B1 (fr)
RU (1) RU2582247C2 (fr)
SG (1) SG190681A1 (fr)
SI (1) SI2640739T1 (fr)
UA (1) UA112420C2 (fr)
WO (2) WO2012066376A1 (fr)
ZA (1) ZA201303042B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10632237B2 (en) 2006-10-09 2020-04-28 Minnetronix, Inc. Tangential flow filter system for the filtration of materials from biologic fluids
WO2012066376A1 (fr) * 2010-11-18 2012-05-24 Centre National De La Recherche Scientifique - Cnrs - Inhibiteurs de l'apoptose et leurs utilisations
GB201314610D0 (en) * 2013-08-15 2013-10-02 Blueberry Therapeutics Ltd Compounds and their uses
CN103585618B (zh) * 2013-10-31 2016-04-06 中山大学 端粒结合蛋白daxx在制备肿瘤细胞调控剂中的应用
KR101909906B1 (ko) * 2015-11-13 2018-10-22 한양대학교 산학협력단 비강 투여를 통한 뇌졸중 치료용 조성물
WO2019195693A1 (fr) * 2018-04-05 2019-10-10 University Of Florida Research Foundation Inhibiteur polypeptidique de la lipogenèse de novo dans des cellules cancéreuses
CN108753820A (zh) * 2018-06-07 2018-11-06 嘉兴学院 Daxx蛋白通过激活erk信号通路促进卵巢癌腹水细胞增殖和转移
CN112679595B (zh) * 2020-04-10 2022-11-01 南京市儿童医院 脑源肽或融合肽在新生儿缺氧缺血性脑损伤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159731A (en) * 1997-02-12 2000-12-12 Massachusetts Institute Of Technology Daxx, a Fas-binding protein that activates JNK and apoptosis
AU2002306500C1 (en) * 2001-02-16 2006-09-28 Cellgate, Inc. Transporters comprising spaced arginine moieties
RU2328273C2 (ru) * 2001-12-19 2008-07-10 Рисерч Дивелопмент Фаундейшн Липосомальная доставка соединений, основанных на витамине е
KR100597615B1 (ko) * 2004-05-07 2006-07-10 주식회사 동부한농 인간 ＮＨＥ1 이온채널 단백질 결합제로서의 인간Ｄａｘｘ 단백질 및 그의 단편
US8809002B2 (en) * 2008-07-10 2014-08-19 Dana-Farber Cancer Institute, Inc. MUC1, caspase-8, and DED-containing proteins
WO2012066376A1 (fr) * 2010-11-18 2012-05-24 Centre National De La Recherche Scientifique - Cnrs - Inhibiteurs de l'apoptose et leurs utilisations

Also Published As

Publication number Publication date
CA3078178C (fr) 2023-07-11
EP2640739B1 (fr) 2015-09-02
ES2653734T3 (es) 2018-02-08
EP2982685B1 (fr) 2017-11-15
CN106188271B (zh) 2019-11-26
EP2640739A2 (fr) 2013-09-25
KR20180119697A (ko) 2018-11-02
SI2640739T1 (sl) 2016-01-29
IL226005A0 (en) 2013-06-27
DK2640739T3 (en) 2015-12-07
NI201300045A (es) 2013-08-01
EP2982685A1 (fr) 2016-02-10
US9814758B2 (en) 2017-11-14
GT201300117A (es) 2015-11-13
AU2011331103A1 (en) 2013-05-23
AU2011331103B2 (en) 2016-11-24
HUE026150T2 (en) 2016-05-30
GEP201606514B (en) 2016-07-25
MX2013005587A (es) 2014-02-03
HRP20151165T1 (hr) 2015-12-18
SG190681A1 (en) 2013-07-31
NZ610620A (en) 2015-01-30
IL257069B (en) 2019-09-26
EA201300592A1 (ru) 2013-10-30
CA2816827A1 (fr) 2012-05-22
UA112420C2 (uk) 2016-09-12
EA027336B1 (ru) 2017-07-31
CY1118022T1 (el) 2017-05-17
CA2816827C (fr) 2020-06-23
CR20130190A (es) 2013-10-07
IL226005B (en) 2018-02-28
CA3078178A1 (fr) 2012-05-22
MY170604A (en) 2019-08-20
CL2013001411A1 (es) 2014-03-28
KR102017645B1 (ko) 2019-09-03
ME02291B (me) 2016-02-20
ZA201303042B (en) 2014-07-30
JP6204828B2 (ja) 2017-09-27
RU2582247C2 (ru) 2016-04-20
CN103403023A (zh) 2013-11-20
WO2012066376A1 (fr) 2012-05-24
WO2012066103A2 (fr) 2012-05-24
WO2012066103A3 (fr) 2012-08-16
US20130288979A1 (en) 2013-10-31
JP2013544249A (ja) 2013-12-12
CO6700879A2 (es) 2013-06-28
HK1184791A1 (zh) 2014-03-07
CN103403023B (zh) 2016-08-17
RS54422B1 (en) 2016-04-28
PT2640739E (pt) 2015-11-30
RU2013127565A (ru) 2014-12-27
ES2553770T3 (es) 2015-12-11
MX345594B (es) 2017-02-07
IL257069A (en) 2018-03-29
PL2640739T3 (pl) 2016-01-29
BR112013012362A2 (pt) 2016-08-30
CN106188271A (zh) 2016-12-07
KR101913285B1 (ko) 2018-10-30
KR20140032955A (ko) 2014-03-17

Similar Documents

Publication Publication Date Title
MA34670B1 (fr) Inhibiteurs de l'apoptose et leurs utilisations
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
WO2016196776A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
EP3147285A3 (fr) Composés de purinone en tant qu'inhibiteurs de kinase
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
MA34474B1 (fr) Agonistes de gpr40
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
TW200806293A (en) Methods of treatment with CETP inhibitors
BRPI0419229A (pt) derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
MX2009002717A (es) Composiciones y metodos para tratamiento del sindrome de fatiga cronica y enfermedades neurodegenerativas.
MA37640B1 (fr) Protéines du facteur de croissance des fibroblastes 21
MA39188A1 (fr) Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci